

**REMARKS**

**FORMAL MATTERS:**

Claims 1-5, 7, 12, 23-29, 31, 36, 52-61, 63, 68, 70, 75, 91-92 and 122-157 are pending after entry of the amendments set forth herein.

Claims 76-90, 93, 98 and 116-121 are canceled without prejudice.

Claims 1, 25, 55 and 59 are amended. Claims 122-157 are new. Support for the amendments and new claims is found, for example, on pages 25 to 29 of the application and claims 12-20 of the application as filed.

No new matter is added.

**REJECTIONS UNDER 35 U.S.C. §102**

Claims 1-4, 7, 12, 23-27, 29, 31, 36, 52-54, 91-92 are rejected under 35 U.S.C. § 102(b) as being anticipated by McVey et al. (J. Biol. Chem. 2001 276: 14092-14099). In making this rejection, the Examiner states: “McVey et al teach a method of detecting human GPCR receptor oligomerization by coexpressing in the same cell and *immunoprecipitating the receptors together* (pages 14092 and 14094)” (italics added).

Claims 1-4, 7, 12, 23-27, 29, 31, 36, 52-61, 63-68, 70, 75 and 91-92 are rejected under 35 U.S.C. § 102(b) as being anticipated by Jordan et al. (Nature 1999 399:697-700). In making this rejection, the Examiner states: “Jordan et al teach a method of detecting human GPCR oligomerization by coexpressing in the same cell different combinations of GPCR and *immunoprecipitating the receptors together* (pages 697-699)” (italics added).

As shown above, the claims have been amended to recite a method that “does *not* comprise immunoprecipitating said first and second polypeptides”. Since McVey and Jordan teach a method that comprises immunoprecipitating, they cannot anticipate the claims and, as such, these rejections should be withdrawn.

Withdrawal of these rejections is requested.

**CONCLUSION**

Applicant submits that all of the claims are in condition for allowance, which action is requested. If the Examiner finds that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number AREN-065.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: June 24, 2010

By: /James S. Keddi, Reg. No. 48,920/  
James S. Keddie, Ph.D.  
Registration No. 48,920

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231